Laura C. Bover, PhD, MSc

Peer-Reviewed Articles

1. Bi E, Li R, Bover LC, Li H, Su P, Ma X, Huang C, Wang Q, Liu L, Yang M, Lin Z, Qian J, Fu W, Liu YJ, Yi Q. E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs. J Clin Invest 128(11):4821-4831, 2018. e-Pub 2018. PMID: 30277474.
2. Qin H, Wei G, Sakamaki I, Dong Z, Cheng WA, Smith DL, Wen F, Sun H, Kim K, Cha S, Bover L, Neelapu SS, Kwak LW. Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug resistant human B-cell malignancies in vivo. Clin Cancer Res 24(5):1114-1123, 2018. e-Pub 2017. PMID: 29180606.
3. Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB, Fueyo J. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res 77(14):3894-3907, 2017. e-Pub 2017. PMID: 28566332.
4. Karjalainen K, Jaalouk DE, Bueso-Ramos C, Bover L, Sun Y, Kuniyasu A, Driessen WH, Cardó-Vila M, Rietz C, Zurita AJ, O'Brien S, Kantarjian HM, Cortes JE, Calin GA, Koivunen E, Arap W, Pasqualini R. Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res 21(13):3041-51, 2015. e-Pub 2015. PMID: 25779950.
5. Puebla-Osorio N, Damiani E, Bover L, Ullrich SE. Platelet-activating factor induces cell cycle arrest and disrupts the DNA damage response in mast cells. Cell Death Dis 6:e1745, 2015. e-Pub 2015. PMID: 25950475.
6. Arumugam T, Deng D, Bover L, Wang H, Logsdon CD, Ramachandran V. New Blocking Antibodies against Novel AGR2-C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice. Mol Cancer Ther 14(4):941-51, 2015. e-Pub 2015. PMID: 25646014.
7. Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE, Kwak LW, Liu YJ, Neelapu SS. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 135(12):2834-46, 2014. e-Pub 2014. PMID: 24771328.
8. Voo KS, Bover L, Harline ML, Weng J, Sugimoto N, Liu YJ. Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells. J Immunol 193(2):627-34, 2014. e-Pub 2014. PMID: 24928999.
9. Hu J, Vien LT, Xia X, Bover L, Li S. Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells. Biol Proced Online 16(1):3, 2014. e-Pub 2014. PMID: 24495546.
10. Voo KS, Bover L, Harline ML, Vien LT, Facchinetti V, Arima K, Kwak LW, Liu YJ. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol 191(7):3641-50, 2013. e-Pub 2013. PMID: 24014877.
11. Bao M, Hanabuchi S, Facchinetti V, Du Q, Bover L, Plumas J, Chaperot L, Cao W, Qin J, Sun SC, Liu YJ. CD2AP/SHIP1 Complex Positively Regulates Plasmacytoid Dendritic Cell Receptor Signaling by Inhibiting the E3 Ubiquitin Ligase Cbl. J Immunol. e-Pub 2012. PMID: 22706086.
12. Talukder AH, Bao M, Kim TW, Facchinetti V, Hanabuchi S, Bover L, Zal T, Liu YJ. Phospholipid Scramblase 1 regulates Toll-like receptor 9-mediated type I interferon production in plasmacytoid dendritic cells. Cell Res. e-Pub 2012. PMID: 22453241.
13. Pedroza-Gonzalez A, Xu K, Wu TC, Aspord C, Tindle S, Marches F, Gallegos M, Burton EC, Savino D, Hori T, Tanaka Y, Zurawski S, Zurawski G, Bover L, Liu YJ, Banchereau J, Palucka AK. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med 208(3):479-90, 2011. e-Pub 2011. PMID: 21339324.
14. Kim T, Pazhoor S, Bao M, Zhang Z, Hanabuchi S, Facchinetti V, Bover L, Plumas J, Chaperot L, Qin J, Liu YJ. Aspartate-glutamate-alanine-histidine box motif (DEAH)/RNA helicase A helicases sense microbial DNA in human plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 107(34):15181-6, 2010. e-Pub 2010. PMID: 20696886.
15. Cao W, Bover L, Cho M, Wen X, Hanabuchi S, Bao M, Rosen DB, Wang YH, Shaw JL, Du Q, Li C, Arai N, Yao Z, Lanier LL, Liu YJ. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 206(7):1603-14, 2009. e-Pub 2009. PMID: 19564354.
16. Voo KS, Wang YH, Santori FR, Boggiano C, Wang YH, Arima K, Bover L, Hanabuchi S, Khalili J, Marinova E, Zheng B, Littman DR, Liu YJ. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A 106(12):4793-8, 2009. e-Pub 2009. PMID: 19273860.
17. Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L, Qin FX, Gilliet M, Liu YJ. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 28(6):870-80, 2008. e-Pub 2008. PMID: 18513999.
18. Cao W, Zhang L, Rosen DB, Bover L, Watanabe G, Bao M, Lanier LL, Liu YJ. BDCA2/Fc epsilon RI gamma complex signals through a novel BCR-like pathway in human plasmacytoid dendritic cells. PLoS Biol 5(10):e248, 2007. PMID: 17850179.
19. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 178(12):8183-94, 2007. PMID: 17548657.
20. Cao W, Rosen DB, Ito T, Bover L, Bao M, Watanabe G, Yao Z, Zhang L, Lanier LL, Liu YJ. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J Exp Med 203(6):1399-405, 2006. e-Pub 2006. PMID: 16735691.
21. Bover L, Kolonin MG, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardo-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res 66(1):34-40, 2006. PMID: 16397212.
22. Mantegazza AR, Barrio MM, Moutel S, Bover L, Weck M, Brossart P, Teillaud JL, Mordoh J. CD63 tetraspanin slows down cell migration and translocates to the endosomal-lysosomal-MIICs route after extracellular stimuli in human immature dendritic cells. Blood 104(4):1183-90, 2004. e-Pub 2004. PMID: 15130945.
23. Capurro M, Ballaré C, Bover L, Portela P, Mordoh J. Differential lytic and agglutinating activity of the anti-Lewis(x) monoclonal antibody FC-2.15 on human polymorphonuclear neutrophils and MCF-7 breast tumor cells. In vitro and ex vivo studies. Cancer Immunol Immunother 48(2-3):100-8, 1999. PMID: 10414463.
24. Bover L, Barrio M, Bravo AI, Slavutsky I, Larripa I, Bolondi A, Ayala M, Mordoh J. The human breast cancer cell line IIB-BR-G has amplified c-myc and c-fos oncogenes in vitro and is spontaneously metastatic in vivo. Cell Mol Biol (Noisy-le-grand) 44(3):493-504, 1998. PMID: 9620446.
25. Capurro M, Bover L, Portela P, Livingston P, Mordoh J. FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes LewisX hapten. Cancer Immunol Immunother 45(45):334-339, 1998. PMID: 9490204.
26. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, Mordoh J, Podhajcer OL. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 3(2):171-6, 1997. PMID: 9018235.
27. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108(2):210-4, 1997. PMID: 9008236.
28. Mordoh J, Kairiyama C, Bover L, Solarolo E. Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study. Medicina (B Aires) 57(4):421-7, 1997. PMID: 9674264.
29. Ledda MF, Adris S, Bravo AI, Bover L, Carbone C, Paleolog E, Mordoh J, Chernajovsky Y, Podhajcer OL. Tumor cells engineered to express Interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model. Cell Mol Biol (Noisy-le-grand) 42(5):769-778, 1996. PMID: 8832108.
30. Morvillo V, Bover L, Mordoh J. Identification and characterization of a 14kDa immunosuppressive protein derived from IIB-MEL-J, a human melanoma cell line. Cell Mol Biol (Noisy-le-grand) 42(5):779-795, 1996. PMID: 8832109.
31. Ledda MF, Adris S, Bover L, Bravo AL, Mordoh J, Podhajcer OL. [The role of SPARC gene in tumorigenic capacity of human melanoma cells]. Medicina (B Aires) 56(1):51-4, 1996. PMID: 8734932.
32. Kairiyama C, Slavutsky I, Larripa I, Morvillo V, Bravo AI, Bover L, Podhajcer OL, Mordoh J. Biologic, immunocytochemical and cytogenetic characterization of two new human melanoma cell lines: IIB-MEL-LES and IIB-MEL-IAN. Pigment Cell Res 8(3):121-131, 1995. PMID: 7567787.
33. Podhajcer OL, Bover L, Bravo AI, Ledda MF, Kairiyama C, Calb I, Guerra L, Capony F, Mordoh J. Expression of cathepsin D in primary and metastatic human melanoma and dysplastic nevi. J Invest Dermatol 104(3):340-4, 1995. PMID: 7860998.
34. Mordoh J, Leis S, Bravo AI, Podhajcer OL, Ballare C, Capurro M, Kairiyama C, Bover L. Description of a new monoclonal antibody, FC-2.15, reactive with human breast cancer and other human neoplasias. Int J Biol Markers 9(3):125-34, 1994. PMID: 7829891.
35. Bover L, Barrio M, Slavutsky I, Bravo AI, Quintans C, Bagnati A, Lema B, Schiaffi J, Yomha R, Mordoh J. Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor. Breast Cancer Res Treat 19(19):47-56, 1991. PMID: 1661624.
36. Guerra L, Bover L, Mordoh J. Differentiating effect of L-tyrosine on the human melanoma cell line IIB-MEL-J. Exp Cell Res 188(188):61-65, 1990. PMID: 2328778.
37. Medrano EE, Resnicoff M, Cafferata EG, Larcher F, Podhajcer O, Bover L, Molinari B. Increased secretory activity and estradiol receptor expression are among other relevant aspects of MCF-7 human breast tumor cell growth which are expressed only in the absence of serum. Exp Cell Res 188(1):2-9, 1990. PMID: 2184046.
38. Podhajcer OL, Resnicoff M, Bover L, Medrano EE, Slavutsky I, Larripa I, Mordoh J. Effect of estradiol and Tamoxifen on the anchorage independent growth of the subpopulations derived from MCF-7 breast carcinoma cells. Cytogenetic analysis of the stem cell subpopulation. Exp Cell Res 179(179):58-64, 1988. PMID: 3169151.
39. Podhajcer OL, Bravo AI, Dain L, Guman N, Bover L, Mordoh J. In vitro analysis of the cellular proliferative response to 17-beta-estradiol of human breast cancer. Cancer 61(9):1807-12, 1988. PMID: 3281743.
40. Sorin I, Bravo AI, Podhajcer OL, Bover L, Loza J, Souza Martinez F, Guman N, Mordoh J. Analysis of DNA-synthesis and CEA expression in human breast cancer. J.Exp.Clin Cancer Res(7):35-42, 1988.
41. Resnicoff M, Medrano EE, Podhajcer OL, Bravo AI, Bover L, Mordoh J. Subpopulations of MCF7 cells separated by Percoll gradient centrifugation: a model to analyze the heterogeneity of human breast cancer. Proc Natl Acad Sci U S A 84(20):7295-9, 1987. PMID: 2823256.
42. Cabral S, Leis S, Bover L, Nembrot M, Mordoh J. Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells. Proc Natl Acad Sci U S A 81(10):3200-3, 1984. PMID: 6587345.

Invited Articles

1. Laura Bover, Mar Naranjo-Gómez, Shino Hanabuchi, Begoña Pérez-Cabezas, and Francesc E. Borràs. Biological aspects of human plasmacytoid dendritic cells and their leukemic counterparts; similarities and differences. Review. Inmunología 29(4):125-134, 2010.
2. Cao W, Bover L. Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells. Immunol Rev 234(1):163-76, 2010. PMID: 20193018.

Other Articles

1. Barrio M, Viaggi M, Donaldson M, Portela P, Bover L, Mordoh J and Castiglia SG Tumor imaging with 99mTc-labeled FC-5.01 monoclonal antibody using a single step labeling method. J. Radioanal. Nucl. Chem 245(2), 2000.
2. Bover L, Bravo AI, Kairiyama C, Solarolo E, Silva C, Chacon R, Mordorh J Clinical Trial: treatment with cyclophopshamide and autologous tumor cells in malignant melanoma. Tumor 5(1):3-8, 1992.
3. Kairiyama C, Leis S, Bover L, Mordoh J, Cymberknop D, Bruno G, Donaldson M, Quintans C Radioimmunodetection of human tumors developed in nude mice with monoclonal antibodies. Public Ordinary Session from the National Academy of Medicine Proceedings, 1990.
4. Bover L, Leis S, Mordoh J Dipyridamole enhances citotoxicity on HEp-2 cells in the presence of thymidine. Tumor. Oncologia Interdisciplinaria. Argentina(1):11-16, 1988.

Abstracts

1. Toniatti C, Yanamandra N, Voo K, Bover L, Al-Shami A, Morley P, Brett S, Lofton T, Greer J, Feng N, Wistuba I, Bhattacharya S, Hopson C, Kilian K, Jackson H, Bojczuk P, Mandal M, Jing J, French K, Srinivasan R, Hoos A. Engaging the immune system with GSK3174998, a potent anti-OX40 agonist antibody. AACR 2016, 2016.
2. Jiang H, CliseDwyer K, Bover L, Lang FF, GomezManzano C, Fueyo J. Potentiation of antiglioma immunity induced by oncolytic adenovirus Delta24RGD through viral expression of immune costimulator OX40 ligand. Society for Immunotherapy of Cancer 30th Annual Meeting, National Harbor, MD (November 48, 2015), 2015.
3. Jiang H, GomezManzano C, CliseDwyre K, Bover L Vence LM, Lang FF, Conrad CA, Toniatti C, Tufaro F, Fueyo J. Delta24RGDOX: Expressing OX40L in gliomas using replication competent oncolytic adenoviruses induces antitumor effect and antiglioma immune memory. CRICIMTEATIAACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, New York, NY (September 1619, 2015), 2015.
4. Jiang H, Fan X, CliseDwyer K, Bover L, Gumin J, Ruisaard KE, Mukheef FJ, Lang FF, GomezManzano C, Fueyo J. Delta24RGDOX: making cancer more “visible” to the immune system. Proceedings of the 2015 Annual Meeting of the American Association for Cancer Research (AACR); 2015 Apr 1822; Philadelphia, PA, 2015.
5. Jiang H, CliseDwyer K, Bover L, Lang FF, Yung WKA, GomezManzano C, Fueyo J. Delta24RGDOX: an oncolytic adenovirus enhances antiglioma immunity through expressing the immune checkpoint costimulator OX40 ligand. 9th International Conference on Oncolytic Virus Therapeutics; Harvard Medical School, June 1316, 2015, Boston, MA, 2015.
6. Jiang H, Lang F, Fan X, Gumin J, Bover L, Clise-Dwyer K, Toniatti C, Ruisaard K, Conrad C, Vence L, Gomez-Manzano C, Fueyo J. Delta-24-RGDOX: Targeting co-stimulatory immune checkpoint proteins with oncolytic adenoviruses. NeuroOncology. 19th Annual Scientific Meeting of the Society for NeuroOncology, November 1316, 2014, Miami, FL 16(suppl.5):v112, 2014.
7. Jiang H, CliseDwyer K, Fan X, GuminJ, Mukheef F, Bover L, Toniatti C, Ruisard K, Vence L, Yung WKA, GomezManzano C, Fueyo J. Enhancement of antitumor immunity induced by OX40 ligandexpressing oncolytic adenovirus Delta24RGDOX. NIH/NCI Cancer Immunology and Immunotherapy: Delivering the Promise, October 910, 2014, Bethesda, MD, 2014.
8. Cao W, Bover L, Cho M, Wen X, Hanabuchi S, Bao M, Rosen DB, Wang YH, Shaw JL, Du Q, Li C, Arai N, Yao Z, Lanier LL, Liu YJ. Identification of a biological ligand for plasmacytoid dendritic cell receptor ILT7. Keystone Symposia Dendritic cells, Banff, Canada, 2009.
9. Ito T, Hanabuchi S, Wang YH, Park WR, Arima K, Bover L, Qin FX, Gilliet M, Liu YJ.. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. The 10th International Symposium on Dendritic Cells, 2008.
10. Cao W, Bover L, Cho M, Hanabuchi S, Bao M, Rosen D, Wang Y-H, Shaw J, Du Q, Arai N, Yao Z, Lanier LL, Liu Y-J. Identification of a Biological Ligand for Plasmacytoid Dendritic Cell receptor ILT7. The 10th International Symposium on Dendritic Cells, Kobe, Japan, 2008.
11. Liu Y-J, Cao W, Bover L. Negative feedback regulation of type 1 IFN response by pDC specific receptor ILT7 and ligand. The 10th International Symposium on Dendritic Cells, Kobe, Japan, 2008.
12. Cao W, Bover L, Wang-Y-H, Rosen D, Arai N, Yao Z, Lanier LL, Liu Y-J. Identification of a Biological Ligand for human Plasmacytoid Dendritic Cell receptor ILT7. 95th Annual Meeting of the American Association of Immunologists /Experimental Biology, 2008.
13. Cao W, Bover L, Wang Y-H, Rosen D, Cho M, Hanabuchi S, Bao M, Shaw J, Du Q, Arai N, Yao Z, Lewis L, Liu Y-J. Bone Marrow Stromal Cell Antigen 2 Is a Breast Cancer-Associated Ligand for Human Plasmacytoid Dendritic Cell Receptor ILT7. American Association of Immunology, San Diego, California, USA, 2008.
14. Cao W, Bover L, Wang Y-H, Rosen D, Cho M, Hanabuchi S, Bao M, Shaw J, Du Q, Arai N, Yao Z, Lewis L, Liu YJ. Bone Marrow Stromal Cell Antigen 2 Is a Breast Cancer-Associated Ligand for Human Plasmacytoid Dendritic Cell Receptor ILT7. DoCM/CCIR Retreat, Houston, TX, 2007.
15. Voo K, Bover L, Neelapu S, Kwak L, Liu YJ. OX40-ligand inhibits function of IL-10-producing intratumoral CD4+CD25 regulatory T cells in human follicular B-cell lymphoma. 94th Annual Meeting of the American Asociation of Immunologits, Miami, FL(178):50.25, 2007.
16. Cao W, Zhang L, Rosen DB, Bover L, Wantanabe G, Bao M, Lanier L, Liu YJ. Plasmacytoid Dendritic Cell Receptor BDCA2/FcepsilonRI gamma Complex Uses BCR-like Signaling Cascade to Modulate Toll-Like Receptor Responses. 94th Annual Meeting of the American Association of Immunologists, Miami, FL, 2007.
17. Cao W, Zhang L, Rosen DB, Bover L, Watanabe G, Bao M, Lanier LL, Liu-Y-J. Plasmacytoid Dendritic Cell Receptor BDCA2/FcepsilonRI gamma Complex Uses BCR-like Signaling Cascade to Modulate Toll-Like Receptor Responses. Keystone Symposium on Intracellular and Intercellular Signaling in Dendritic Cell Function, Keystone, Colorado, 2007.
18. Cao W, Rosen DB, Ito T, Bover L, Watanabe G, Zhang L, Lanier LL, Liu-Y-J. Plasmacytoid Dendritic Cell-Specific Receptor ILT7/Fc-epsilonRI gamma Inhibits Toll-Like receptor-induced interferon production. 45th Midwinter Conference of Immunologists, Asilomar, Califormia, 2006.
19. Jaalouk D, Kuniyasu A, Marini F, Ranta T-M, Giordano R, Bover L, Sun C, Koivunen E, Arap W, Pasqualini R. Identification of Therapeutic Targets for Leukemia by Phage Display Profiling of Leukemia Cell Lines and Patient-derived Samples, 2005.
20. Jaalouk D, Kuniyasu A, Marini F, Ranta T-M, Giordano R, Bover L, Sun C, Koivunen E, Arap W, Pasqualini R. Identification of Therapeutic Targets for Leukemia by Phage Display Profiling of Leukemia Cell Lines and Clinical Samples, 2004.
21. Longhi P, Machiavelli L, Bover L, Barrio M, Von Euw E, Mordoh J. Preclinical studies of a human vaccine based on dendritic cells loaded with apoptotic/necrotic melanoma cells. Proceedings of the American Association for Cancer Research, Vol. 45. AACR 95st Annual Meeting, Orlando, Florida, USA. April 2004 45, 2004.
22. Bover L, Holbeck S, Scudiero D, Zurita A, Sausville E, Pasqualini R, Arap W. Targeting the NCI 60-cell panel by biopanning and rapid analysis of selective interactive ligands. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston 2003, 2003.
23. Mordoh J, Barrio M, Bover L, Motta P, Kaplan J, Bravo I. A Phase I Vaccination Trial of VACCIMEL and GM-CSF in melanoma patients. Cancer Vaccines 2003. Cancer & HIV Vaccines: Shared Lessons. New York, USA. October 2003, 2003.
24. Bover L, Holbeck S, Scudiero D, Sausville E, Pasqualini R, Arap W. Targeting the NCI 60-cell panel by biopanning and rapid analysis of selective interactive ligands. Proceedings of the American Association for Cancer Research, AACR 94th Annual Meeting, Toronto, Canada 44, 2003.
25. Longhi P, Machiavelli L, Bover L, Barrio M, Mordoh J. Differential induction of dendritic cell maturation and T cell stimulation by phagocytosis of apoptotic and necrotic human melanoma cells. International Symposium on Dendritic Cells and Immunotherapy. Buenos Aires, 2002, 2002.
26. Mantegazza A, Barrio M, Gruel N, Moutel S, Bover L, Teillaud JL, Mordoh J. Targeting of MHC class II compartments in human immature dendritic cells by internalization of the surface complex tetraspanin CD63-FC-5.01 monoclonal antibody. Proceedings of the American Association for Cancer Research, AACR 93rd Annual Meeting, San Francisco 43, 2002.
27. Bover LC, Ochoa M, Lopez Haber C, Cacici G, Barrio MM, Mordorh J. Vaccination with irradiated B16 melanoma cells and recombinant murine granulocyte macrophage colony stimulating factor (rmGM-CSF) stimulates specific anti-tumor response and inhibits tumor growth in the B16F1/C57B1 model. Proceedings of the American Association for Cancer Research, AACR 93rd Annual Meeting, San Francisco 43, 2002.
28. Goldszmid SR, Bover L, Mordoh J Wainstok R. Immunization with dendritic cells loaded with B16F1 melanoma apoptotic cells induces protection against tumor development in C57BL6 mice. Dendritic Cells-Keystone Symposia, 2001, 2001.
29. Bover L, Ochoa M, Lopez Haber C, Mordoh J. Vaccination with irradiated B16 melanoma cells and recombinant murine granulocyte macrophage colony stimulating factor (rmGM-CSF) stimulates specific anti-tumor response and inhibits tumor growth in C57B1 mice. Cancer Vaccines Meeting-CRI:85, 2000.
30. Mantegazza A, Barrio M, Bover L, Moutel S, Gruel N, Teillaud JL, Mordoh J. Construction of scFV-5.01 reactive with tetraspanin CD63. XXXVI International Meeting of Argentine Society of Biochemistry Research and Molecular Biology (SAIB), in association with Spanish Society of Biochemistry and Molecular Biology 24:94, 2000.
31. Schiaffi J, Bover L, Scarano D, Bravo AI, Bagnati A, Machiavelli L, Urrutia A, Yomha R, Mordoh J. Phase I study of monoclonal antibody FC-2.15 and chemotherapy with Fluoruracil-Epirubicin-Cyclophosphamide in advanced breast cancer patients. Proceedings of the American Association for Cancer Research, AACR 91st Annual Meeting, San Francisco 41, 2000.

Book Chapters

1. Bover L, Barrio M, Mordoh J. Mechanisms of Tumor Immuno-evasion. In: Molecular Immunopathology. 1st: Argentina, 2004.